Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Definiens Ink High-Content Screening Technology Deal

NEW YORK, May 9 (GenomeWeb News) - Cenix BioScience and Definiens said today that they have signed a licensing and co-marketing agreement in the area of high-content screening.


Under the deal, Cenix will gain access to Definiens' Cellenger image analysis software system, integrating it into its high-throughput, high-content RNAi-based screening infrastructure. In exchange, Definiens will receive product development and marketing assistance from Cenix through beta-testing feedback, data sharing, and reference site support, the companies said.


Additional terms of the non-exclusive agreement were not disclosed.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.